Titanium Anticancer Drugs

After the discovery of the tumor-inhibiting properties of cis-diammine dichloro-platinum(II) (cisplatin) in 196912 and its routine use as a leading cytostatic drug since 1979,13 there has been increasing interest in the development of new anti-tumor metal agents including non-platinum metal complexes. Among these, two monomeric titanium(IV) complexes have qualified for clinical trials (Figure 7.1) TiIV(bzac)2(OEt)2 (budotitane) and Cp2TiIVCl2 (titanocene dichloride). Relevant reviews on...